Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027
Summary The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight major markets (8MM) ( US, France, Germany, Italy, Spain, UK, Japan, and urban China) representing a compound annual growth rate (CAGR) of 7.5.
Glioblastoma Multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. Although Glioblastoma Multiforme (GBM) is a rare disease, the high level of unmet need in this market creates ample opportunities for players with effective therapies.
However, there is a significant lack of effective therapies in the current market due to the inability of drugs to penetrate the blood-brain barrier (BBB).The only targeted agent approved for recurrent Glioblastoma Multiforme (GBM) patients is Roche’s Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China.
Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.
Since Glioblastoma Multiforme (GBM) patients have no effective treatment options and low survival expectancy, there is the potential for high uptake in the market if an agent is capable of increasing survival or quality of life.Although progress has been made, survival rates are still dismal.
Therapies that can prolong the overall survival (OS) of patient’s refractory to Avastin are the greatest unmet need in the Glioblastoma Multiforme (GBM) space; fulfilling this need is a safe route to regulatory approval and commercial success.
Like other orphan indications with high levels of unmet need, it is clear that effective therapies for Glioblastoma Multiforme (GBM) can demand premium pricing.Although Glioblastoma Multiforme (GBM) affects a relatively small number of patients, there are seven drugs in the late stages of development.
These include Opdivo, DCVax-L, and depatuxizumab mafodotin, which have shown promising efficacy in early-stage trials. The level of unmet need for Glioblastoma Multiforme (GBM) patients is exceedingly high, which will facilitate the adoption of these new drug candidates.
The latest report "Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027", states that a drive to address the high level of unmet needs will be hindered by difficulties in clinical development, leading to only modest growth in the Glioblastoma Multiforme (GBM) market.
Scope - Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. - Annualized GBM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market. - Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for GBM. The most promising candidates in late-stage development are profiled. - Analysis of the current and future market competition in the global GBM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global GBM market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Our reports have been used by over 10K customers, including:
Protein Phosphatase 2A - Pipeline Review, H2 2020 Summary According to the recently published report ’Protein Phosphatase 2A - Pipeline Review, H2 2020’; Protein Phosphatase 2A (PP2A or EC 220.127.116.11) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed...
Gliosarcoma Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Gliosarcoma Global Clinical Trials Review, H2, 2020" provides an overview of Gliosarcoma Clinical trials scenario.This report provides top line data relating to the clinical trials on Gliosarcoma. Report includes...
Anal Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides an overview of the Anal Cancer (Oncology) pipeline landscape. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal...
Osteosarcoma - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2020, provides an overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone that destroys...
Bone Metastasis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2020, provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells spread from their...
Oropharyngeal Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.